VP, Head of Preclinical Development at Dyne Therapeutics
John brings nearly 20 years of experience in a global biopharmaceutical setting with expertise managing both exploratory and GLP nonclinical toxicology studies. John’s breadth of portfolio support includes antisense oligonucleotide, small molecule and biologic programs, across many therapeutic areas and all stages of development. Prior to joining Dyne, John was vice president of preclinical development at Wave Life Sciences where he established toxicology as a core discipline and led cross-functional teams aimed at developing and implementing early safety screening strategies. Prior to Wave, John held positions of increasing responsibility at first Schering-Plough and then Pfizer. While at Pfizer, John was a recognized leader in developing mechanism-based human risk assessment projects and led highly effective cross-discipline teams driving novel approaches to toxicology studies. John received his Ph.D. in molecular toxicology from Purdue University and his B.S. from the University of Wisconsin-Madison.